中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
18期
8206-8208
,共3页
潘闻%鲍旭丽%王金环%李红霞%渠亚超
潘聞%鮑旭麗%王金環%李紅霞%渠亞超
반문%포욱려%왕금배%리홍하%거아초
氟伐他汀%高胆固醇血症%肝炎,丙型,慢性
氟伐他汀%高膽固醇血癥%肝炎,丙型,慢性
불벌타정%고담고순혈증%간염,병형,만성
Fluvastatin%Hypercholesterolemia%Hepatitis C,Chronic
目的:观察氟伐他汀对合并高胆固醇血症的慢性丙型肝炎的抗病毒疗效的影响。方法选取2006年9月至2008年9月合并高胆固醇血症慢性丙型肝炎60例,观察组30例,对照组30例,所有患者均予聚乙二醇干扰素α-2a+利巴韦林治疗;观察组患者加用氟伐地汀;用药后4、12、24、36、48周及停药后12周、24周复查病毒RNA定量。结果氟伐他汀治疗合并高LDL血症的慢性丙型肝炎的患者的早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)均显著高于对照组(53.3%vs.46.7%,85.1%vs.63.3%,81.5%vs.53.3%,P<0.05)。结论氟伐他汀有利于提高合并高胆固醇血症的慢性丙型肝炎患者的抗病毒疗效。
目的:觀察氟伐他汀對閤併高膽固醇血癥的慢性丙型肝炎的抗病毒療效的影響。方法選取2006年9月至2008年9月閤併高膽固醇血癥慢性丙型肝炎60例,觀察組30例,對照組30例,所有患者均予聚乙二醇榦擾素α-2a+利巴韋林治療;觀察組患者加用氟伐地汀;用藥後4、12、24、36、48週及停藥後12週、24週複查病毒RNA定量。結果氟伐他汀治療閤併高LDL血癥的慢性丙型肝炎的患者的早期病毒學應答(EVR)、治療結束時病毒學應答(ETVR)和持續病毒學應答(SVR)均顯著高于對照組(53.3%vs.46.7%,85.1%vs.63.3%,81.5%vs.53.3%,P<0.05)。結論氟伐他汀有利于提高閤併高膽固醇血癥的慢性丙型肝炎患者的抗病毒療效。
목적:관찰불벌타정대합병고담고순혈증적만성병형간염적항병독료효적영향。방법선취2006년9월지2008년9월합병고담고순혈증만성병형간염60례,관찰조30례,대조조30례,소유환자균여취을이순간우소α-2a+리파위림치료;관찰조환자가용불벌지정;용약후4、12、24、36、48주급정약후12주、24주복사병독RNA정량。결과불벌타정치료합병고LDL혈증적만성병형간염적환자적조기병독학응답(EVR)、치료결속시병독학응답(ETVR)화지속병독학응답(SVR)균현저고우대조조(53.3%vs.46.7%,85.1%vs.63.3%,81.5%vs.53.3%,P<0.05)。결론불벌타정유리우제고합병고담고순혈증적만성병형간염환자적항병독료효。
Objective To investigate the efficacy of fluvastatin on antiviral treatment on the patients with chronic hepatitis C and hypercholesterolemia. Methods Sixty patients with chronic hepatitis C and hypercholesterolemia in September 2006 to September 2008 in Youan Hospital divided into observation group and control group, 30 cases each group. All patients were treated with peginterferon α-2a and ribavirin. The patients in investigation group were treated with fluvastatin additionally. The HCV RNA number were tested at 4, 12, 24, 48 weeks after treatment initiation and at 12 and 24 weeks after termination. Rusults Both early virological response and sustained virological response of investigation group were much higher than those of control group(53.3% vs 46.7%, 81.5%vs 53.3%, P<0.05). Conclusion Fluvastatin might be benefit to the patients with chronic hepatitis C and hypercholesterolemia.